ClinicalTrials.gg
CompletedNCT05575024HISTORIXUpdated Nov 19, 2026

Hemodynamic Stability in Septic Shock Patients Undergoing Continuous Renal Replacement Therapy With oXiris Membrane

An observational study in Acute Kidney Injury Due to Sepsis, sponsored by Seoul National University Hospital. Completed at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Seoul National University Hospital · Observational

How we know

Updated Nov 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
98
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Acute Kidney Injury by Seoul National University Hospital — 3 open to participants now, 3 under way, none of them phase 3. Acute Kidney Injury · Seoul National University Hospital.

Started
2024
the only one that year
Observational
7 of 18
1 open now
Registered
14th of 18
by date

Among the 18 studies in Acute Kidney Injury by Seoul National University Hospital, this one is the only one that started in 2024, is one of 7 observational ones, and was the 14th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

3 of the 18 studies in Acute Kidney Injury by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Acute Kidney Injury by Seoul National University Hospital, or all of them as a file.
02

Study summary

The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in septic shock patients with severe acute kidney injury, compared with standard membranes. However, its hemodynamic stability or benefits have not been thoroughly evaluated although this is reasonable.

Read the detailed description

The new adsorbing membrane for continuous renal replacement therapy (CRRT), oXiris, can reduce plasma cytokines and endotoxins in patients with severe acute kidney injury or sepsis, compared with standard membranes. Based on this benefit, the use of oXiris may confer better outcomes than other membranes.

The patient outcomes include cardiovascular, respiratory, renal, and overall survivals, but this information of oXiris are insufficient. Although cytokine and endotoxin removal rates are great in oXiris, the beneficial effects on the hard outcomes are needed to use oXiris in real clinical practice.

The inflammatory and cardiovascular systems have intensive crosstalk, and thus if there are remission in inflammatory process, the patients can have hemodynamic stability. Regarding this, the investigators would like to compare the hemodynamic stability between oXiris and other standard membrane such as polysulfone, using our new real-time monitoring registry.

03

Conditions studied

  • Acute Kidney Injury Due to Sepsis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients who have severe acute kidney injury and require continuous renal replacement therapy because of hemodynamic instability.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥ 18 years
  • Sepsis related acute kidney injury requiring continuous renal replacement therapy

Exclusion criteria

Exclusion Criteria:

  • No monitoring of blood pressure and
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
98 participants (actual)
Patient registry
No

Groups and cohorts

  • Septic AKI

    Patients with septic acute kidney injury requiring continuous renal replacement therapy

    Device: oXiris membrane · Device: Polysulfone membrane

Interventions

  • DeviceoXiris membrane

    Perform continuous renal replacement therapy with oXiris membrane

  • DevicePolysulfone membrane

    Perform continuous renal replacement therapy with polysulfone membrane

06

What researchers measure

Primary outcomes

  1. Rate of all-cause mortality

    Risk of all-cause mortality

    Time frame: 28 days

  2. Occurrence rates of ventricular tachycardia, intradialytic hypotension

    Risk of ventricular tachycardia, intradialytic hypotension

    Time frame: 28 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Dec 2025, 23 months.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's 23 months is close to that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jun 2026 → Dec 2025 and completion Dec 2026 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2022
First posted
Oct 12, 2022
StartActual
Jan 1, 2024
Primary completionActual
Dec 26, 2025was Jun 2026
CompletionActual
Dec 31, 2025was Dec 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 19, 2026
Primary completion
Jun 30, 2026→Dec 26, 2025 (actual)
Nov 19, 2026
Study completion
Dec 31, 2026→Dec 31, 2025 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Completed
    Primary completion Jun 30, 2026→Dec 26, 2025 (now actual)
    Study completion Dec 31, 2026→Dec 31, 2025 (now actual)
    + 4 other changes: verification date, oversight details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05575024
Responsible party
Seung Seok Han, MD (Associate Professor, Seoul National University Hospital) — Principal investigator
First posted
Oct 12, 2022
Start date
Jan 1, 2024
Primary completion
Dec 26, 2025
Completion
Dec 31, 2025
Last update
Nov 19, 2026

Study contacts

Seung Seok Han, M.D.
principal investigator · Seoul National University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion